LIXT — Lixte Biotechnology Holdings Inc
NASDAQ · Healthcare · Biotechnology
$4.18
-$0.02 (-0.48%)
Lixte Biotechnology Holdings Inc (LIXT) is a biotechnology company listed on NASDAQ. It is led by Geordan G. Pursglove, based in 433 Plaza Real, Boca Raton, FL, United States, 33432, with about 3 employees. Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.
Net income was -$2.0M. LIXT currently screens at market cap $121.0M.
Use this LIXT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LIXT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LIXT SEC filings page. Lician reads the product cache first so this HTML stays unique to Lixte Biotechnology Holdings Inc even when a live quote feed is slow.
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.
LIXT Key Statistics
Market Cap
$121.01M
Volume
102,700
Previous Close
$4.20
Day Range
$4.03 – $4.31
P/B Ratio
15.15
EPS
-$1.59
Revenue
$0.00
Net Income
-$3.59M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
3
LIXT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$3.59M | -$5.09M | -$6.31M | -$6.73M |
| EPS (Diluted) | -$1.59 | -$2.66 | -$3.99 | $0.00 |
Total Assets
$1.15M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.04M
Operating Cash Flow
-$3.16M
Free Cash Flow
$0.00
Lixte Biotechnology Holdings Inc Company Information
- CEO, President & Chairman
- Geordan G. Pursglove
- Headquarters
- 433 Plaza Real, Boca Raton, FL, United States, 33432
- Website
- lixte.com
- Phone
- 631 830 7092
- IPO / Founded
- 2007-09-21
- Sector
- Healthcare
- Industry
- Biotechnology